NewSquare Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

NewSquare Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-115	Closed	-$51.2K	–	1205
2025 Q2	$51.2K	Sell	115 -12	-9%	-$5.53K	﹤0.01%	287
2025 Q1	$61.6K	Buy	127 +117	+1,170%	+$54.5K	0.01%	221
2024 Q4	$4.03K	Buy	+10	New	+$4.63K	﹤0.01%	395
2023 Q4	–	Sell	-59	Closed	-$20.5K	–	633
2023 Q3	$20.5K	Buy	59 +49	+490%	+$17.1K	﹤0.01%	245
2023 Q2	$3.52K	Hold	10	–	–	﹤0.01%	460
2023 Q1	$3.15K	Hold	10	–	–	﹤0.01%	511
2022 Q4	$2.89K	Buy	+10	New	+$3.05K	﹤0.01%	436
2020 Q3	–	Sell	-5,535	Closed	-$1.61M	–	411
2020 Q2	$1.61M	Buy	5,535 +980	+22%	+$266K	0.27%	83
2020 Q1	$1.08M	Buy	+4,555	New	+$1.04M	0.2%	86
2016 Q4	–	Sell	-151	Closed	-$13K	–	454
2016 Q3	$13K	Hold	151	–	–	﹤0.01%	241
2016 Q2	$13K	Sell	151 -20	-12%	-$1.73K	﹤0.01%	242
2016 Q1	$14K	Buy	171 +153	+850%	+$13.8K	﹤0.01%	260
2015 Q4	$2K	Hold	18	–	–	﹤0.01%	315
2015 Q3	$2K	Hold	18	–	–	﹤0.01%	285
2015 Q2	$2K	Hold	18	–	–	﹤0.01%	317
2015 Q1	$2K	Hold	18	–	–	﹤0.01%	288
2014 Q4	$2K	Hold	18	–	–	﹤0.01%	292
2014 Q3	$2K	Hold	18	–	–	﹤0.01%	301
2014 Q2	$2K	Buy	+18	New	+$1.26K	﹤0.01%	258

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

NewSquare Capital's VRTX Position: Q3 2025 in Review

NewSquare Capital sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 115 shares — an estimated $51.2K sold.

NewSquare Capital first reported a position in VRTX in Q2 2014 and held it in 19 quarters. The position peaked at $1.61M in Q2 2020. 1,523 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

NewSquare Capital reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
NewSquare Capital sold 115 Vertex Pharmaceuticals shares in Q3 2025, an estimated $51.2K.
NewSquare Capital first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 19 quarters.
NewSquare Capital's Vertex Pharmaceuticals position peaked at $1.61M in Q2 2020.
1,523 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on NewSquare Capital's 13F filing for Q3 2025, filed 12 Nov 2025.